Clinical Trial Indicates High Sensitivity for Exact Sciences DNA-based Colorectal Cancer Screening Test | GenomeWeb

NEW YORK (GenomeWeb News) – Researchers reported in the New England Journal of Medicine this week that, in a clinical study, a DNA-based colorectal cancer screening test was better able to detect instances of cancer than a standard immunochemical test.

The test, Exact Sciences' Cologuard, examines DNA methylation markers, mutation markers, and more in combination with hemoglobin levels in patients' stool samples to determine the presence of colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.